Cargando…
Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer
SIMPLE SUMMARY: For 20 years, the CA 19-9 blood test has been the only broadly used biomarker of pancreatic ductal adenocarcinoma (PDAC). We lack easily available biomarkers to help differentiate patients between good, intermediate and poor survivors at the time of PDAC diagnosis. Using one of the l...
Autores principales: | Kjaergaard, Alisa D., Chen, Inna M., Johansen, Astrid Z., Nordestgaard, Børge G., Bojesen, Stig E., Johansen, Julia S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466571/ https://www.ncbi.nlm.nih.gov/pubmed/34572824 http://dx.doi.org/10.3390/cancers13184599 |
Ejemplares similares
-
Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020) -
Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer
por: Lindgaard, Sidsel C., et al.
Publicado: (2022) -
Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy
por: Lindgaard, Sidsel C., et al.
Publicado: (2022) -
Genetically low vitamin D concentrations and increased mortality: mendelian randomisation analysis in three large cohorts
por: Afzal, Shoaib, et al.
Publicado: (2014) -
AHRR (cg05575921) hypomethylation marks smoking behaviour, morbidity and mortality
por: Bojesen, Stig E, et al.
Publicado: (2017)